Efficacy and Safety of Telmisartan Compared With Losartan
Phase 4
Recruiting
- Conditions
- Diabetic NephropathiesHypertension
- Interventions
- Registration Number
- NCT06431477
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Brief Summary
A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension
- Detailed Description
A Multi-center, Randomized, Open-label, Active comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared with Losartan in Patients with Diabetic Nephropathy and Hypertension
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 98
Inclusion Criteria
- Male of Female subjects aged ≥19 or <75
- Type II Diabetes Mellitus subjects who have been taken medicine
- Subjects who have voluntarily decided to participate in this clinical trial and Signed ICF
Exclusion Criteria
- Subjects with Type I Diabetes Mellitus
- Subjects with Primary hyper-aldosteronism
- Subjects with a history of drug or alcohol abuse or suspected patient within 1 year as of the time of screening
- Pregnant women, lactating women, or subjects who do not agree to use appropriate contraception during the clinical trial period
- Subjects who received other clinical trial drugs within 28 days of screening visit
- Subjects who are unable to participate in this clinical trial at the discretion of the investigator.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Telmisartan tablet telmisartan - Losartan tablet Losartan -
- Primary Outcome Measures
Name Time Method Change rate from baseline in Spot-UACR(Albumin/Creatinine Ratio) 24 weeks after drug administration
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Severance Hospital
🇰🇷Seoul, Korea, Republic of